CLS Americas Inc. and URN Announce Clinical Study “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low to Intermediate Risk Prostate Cancer”
Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System will be used by Focalyx Technologies, developer of image-guided fusion target devices, to conduct a 20-patient, Phase I clinical study titled, “Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-to-Intermediate Risk Prostate Cancer.”CLS Americas Inc, a subsidiary of Clinical Laserthermia Systems AB, today announced the company’s TRANBERG® Thermal Therapy System